DE602004029767D1 - DETECTION, MONITORING AND TREATMENT OF CANCER - Google Patents
DETECTION, MONITORING AND TREATMENT OF CANCERInfo
- Publication number
- DE602004029767D1 DE602004029767D1 DE602004029767T DE602004029767T DE602004029767D1 DE 602004029767 D1 DE602004029767 D1 DE 602004029767D1 DE 602004029767 T DE602004029767 T DE 602004029767T DE 602004029767 T DE602004029767 T DE 602004029767T DE 602004029767 D1 DE602004029767 D1 DE 602004029767D1
- Authority
- DE
- Germany
- Prior art keywords
- detection
- treatment
- cancer
- monitoring
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001514 detection method Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108091023037 Aptamer Proteins 0.000 abstract 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
There are disclosed aptamer ligands to MUC1, preferably comprising a sequence selected from:
and compounds comprising these aptamers and sequences. There are also disclosed compounds having the structure There are also disclosed methods of treatment, diagnosis, detection and imaging using these compounds, their use in such methods, and their use in the preparation of medicaments and products for such methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0305422.8A GB0305422D0 (en) | 2003-03-10 | 2003-03-10 | Detection, monitoring and treatment of cancer |
PCT/GB2004/001028 WO2004081574A2 (en) | 2003-03-10 | 2004-03-10 | Detection, monitoring and treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004029767D1 true DE602004029767D1 (en) | 2010-12-09 |
Family
ID=9954463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004029767T Expired - Lifetime DE602004029767D1 (en) | 2003-03-10 | 2004-03-10 | DETECTION, MONITORING AND TREATMENT OF CANCER |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070160526A1 (en) |
EP (4) | EP1806585A1 (en) |
AT (1) | ATE486284T1 (en) |
CA (1) | CA2518783A1 (en) |
DE (1) | DE602004029767D1 (en) |
GB (1) | GB0305422D0 (en) |
WO (1) | WO2004081574A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4899065B2 (en) * | 2005-08-23 | 2012-03-21 | 国立大学法人群馬大学 | Singlet oxygen generator with silicon-containing substituents |
GB2437727B (en) * | 2006-05-04 | 2011-04-20 | Univ Open | Aptamers directed to MUC1 |
WO2007128109A1 (en) * | 2006-05-04 | 2007-11-15 | University Health Network | Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac) |
JP5841046B2 (en) * | 2009-04-08 | 2016-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Human protein scaffold with controlled serum pharmacokinetics |
EP2481800B1 (en) * | 2009-06-01 | 2018-02-21 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof |
CN103160513B (en) * | 2011-12-16 | 2015-07-01 | 中国医学科学院基础医学研究所 | MUC1 protein nucleic acid aptamer, complex, composition and purposes thereof |
EP2639227A1 (en) * | 2012-03-14 | 2013-09-18 | Bracco Imaging S.p.A | A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents |
WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
AU2015213483B2 (en) | 2014-02-05 | 2020-07-02 | Deakin University | Aptamer construct |
CN105879027B (en) * | 2014-05-16 | 2020-03-27 | 中国科学院苏州纳米技术与纳米仿生研究所 | Nucleic acid ligand modified gold nano-graphene composite material and preparation method and application thereof |
WO2016183207A1 (en) * | 2015-05-11 | 2016-11-17 | Northwestern University | Cyclen friction modifiers for boundary lubrication |
WO2020230047A1 (en) * | 2019-05-15 | 2020-11-19 | Affinito Alessadra | Aptamers against glioblastoma |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915958A (en) | 1972-05-22 | 1975-10-28 | Icn Pharmaceuticals | 6-Substituted purine nucleotides |
US3960840A (en) | 1972-12-29 | 1976-06-01 | University Of Illinois Foundaton | Fluorescent derivatives of adenine-containing compounds |
US4038480A (en) | 1973-09-17 | 1977-07-26 | Icn Pharmaceuticals, Inc. | 6-aminocarbonyl purine 3',5'-cyclic nucleotides |
DE2546073A1 (en) | 1974-10-15 | 1976-04-22 | Asahi Chemical Ind | NUCLEOTIDE DERIVATIVES AND THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE IN MEDICINAL PRODUCTS |
US3968101A (en) | 1974-12-20 | 1976-07-06 | Icn Pharmaceuticals, Inc. | 8-Substituted cyclic nucleotides by free radical alkylation and acylation |
US4048307A (en) | 1974-12-26 | 1977-09-13 | Asahi Kasei Kogyo Kabushiki Kaisha | Cyclic adenosine monophosphate 8-substituted derivatives |
US4267171A (en) | 1979-07-02 | 1981-05-12 | The Regents Of The University Of California | C-5 Substituted cytosine nucleosides |
US6280932B1 (en) * | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
US6268350B1 (en) * | 1997-10-23 | 2001-07-31 | Biocrystal Ltd. | Polynucleotides for inhibiting metastasis and tumor cell growth |
US6418338B1 (en) * | 1998-02-06 | 2002-07-09 | Phylatron Ltd. | Method for detecting and surgically removing lymphoid tissue involved in tumor progression |
US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
WO2000035488A2 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6251616B1 (en) * | 1999-01-14 | 2001-06-26 | Biocrystal Ltd. | Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response |
WO2001052899A1 (en) | 2000-01-21 | 2001-07-26 | Mallinckrodt Inc. | Chelating agents and method for their use as tandem metal chelators and hydrophilic spacers for medical diagnosis and therapy |
US6673333B1 (en) * | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
US6376190B1 (en) * | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
AU2002239468A1 (en) * | 2000-10-31 | 2002-05-27 | Bracco International B.V. | Conjugates of an antioxidants with metal chelating ligands |
KR20040004578A (en) | 2001-04-24 | 2004-01-13 | 대한제당 주식회사 | Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same |
JP2005533794A (en) * | 2002-06-18 | 2005-11-10 | アーケミックス コーポレイション | Aptamer-toxin molecules and methods of using the same |
-
2003
- 2003-03-10 GB GBGB0305422.8A patent/GB0305422D0/en not_active Ceased
-
2004
- 2004-03-10 WO PCT/GB2004/001028 patent/WO2004081574A2/en active Application Filing
- 2004-03-10 EP EP07100346A patent/EP1806585A1/en not_active Withdrawn
- 2004-03-10 US US10/548,718 patent/US20070160526A1/en not_active Abandoned
- 2004-03-10 AT AT04719000T patent/ATE486284T1/en not_active IP Right Cessation
- 2004-03-10 EP EP04719000A patent/EP1601970B1/en not_active Expired - Lifetime
- 2004-03-10 EP EP10157616A patent/EP2209000A3/en not_active Withdrawn
- 2004-03-10 EP EP10181276A patent/EP2287613A2/en not_active Withdrawn
- 2004-03-10 DE DE602004029767T patent/DE602004029767D1/en not_active Expired - Lifetime
- 2004-03-10 CA CA002518783A patent/CA2518783A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1601970B1 (en) | 2010-10-27 |
WO2004081574A2 (en) | 2004-09-23 |
EP1601970A2 (en) | 2005-12-07 |
EP2287613A2 (en) | 2011-02-23 |
WO2004081574A3 (en) | 2004-12-16 |
ATE486284T1 (en) | 2010-11-15 |
GB0305422D0 (en) | 2003-04-16 |
EP2209000A2 (en) | 2010-07-21 |
EP2209000A3 (en) | 2010-10-27 |
EP1806585A1 (en) | 2007-07-11 |
CA2518783A1 (en) | 2004-09-23 |
US20070160526A1 (en) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60303238D1 (en) | Pyrimidine-acetic acid derivatives suitable for the treatment of CRTH2-related diseases | |
ATE527241T1 (en) | PYRIDIAZINONE DERIVATIVES FOR THE TREATMENT OF TUMORS | |
DE602004026891D1 (en) | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | |
ATE424386T1 (en) | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN-MEDIATED DISEASES | |
DE602004020072D1 (en) | 1,2,3,4-TETRASUBSTITUTED INDOL FOR THE TREATMENT OF RESPIRATORY DISEASES | |
ATE478082T1 (en) | PHOSPHONATES, MONOPHOSPHONAMIDATE, BISPHOSPHONAMIDATE FOR THE TREATMENT OF VIRAL DISEASES | |
ATE453653T1 (en) | PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS | |
ATE390925T1 (en) | USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT MYCOBACTERIAL DISEASES | |
ATE486284T1 (en) | DETECTION, MONITORING AND TREATMENT OF CANCER | |
CY1106386T1 (en) | SUBSTITUTED 3-PYRROLIDINE-INDOLE DERIVATIVES | |
DE602006007481D1 (en) | 5-AMINO-4-HYDROXY-7- (IMIDAZOE1,2-ATPYRIDIN-6-YLMETHYL) -8-METHYLNONAMID DERIVATIVES AND RELATED COMPOUNDS AS RENININHIBITORS FOR TREATING BLOOD HIGH PRESSURE | |
DE602005012481D1 (en) | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8- (1H-INDOL-5-YL) -OCTANAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF BLOOD HIGH PRESSURE | |
WO2003087831A3 (en) | Proteins involved in breast cancer | |
ATE448232T1 (en) | SUBSTITUTED HETEROCYCLES | |
CY1111022T1 (en) | NEW PHARMACEUTICAL COMBINATIONS FOR THE RESPIRATORY DISEASE TREATMENT | |
NO994932L (en) | Mixtures and Methods for Treating and Diagnosing Breast Cancer | |
ATE443704T1 (en) | PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISEASES | |
DE602004003952D1 (en) | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS SUITABLE FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | |
CY1114757T1 (en) | OXAZINE PRODUCTS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
DE602006003094D1 (en) | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCHINOLINE DERIVATIVES FOR THE TREATMENT OF BARRENESS | |
DE602005019341D1 (en) | System for the treatment of sterilization cassettes with visual dual-code reader | |
ATE424823T1 (en) | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCINOLINE DERIVATIVES AS MEDICINAL PRODUCTS FOR THE TREATMENT OF INFERTILITY | |
CY1110043T1 (en) | 2-AMINOBENZOUL PRODUCTS | |
DE602005015434D1 (en) | MEANS FOR THE TREATMENT OF PSYCHONEUROTIC DISEASES | |
MXPA01010186A (en) | Compositions and methods for the treatment and diagnosis of breast cancer. |